Midbrain Dopaminergic Progenitor Cell Expansion After CD166 Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing midbrain dopaminergic progenitor cells are limited by the starting number of pluripotent stem cells utilized, leading to inefficiencies in producing large numbers of these cells, and there is a need for methods to obtain cell populations capable of treating neurodegenerative diseases.
Innovation Solution
A method involving the purification and expansion of midbrain dopamine (mDA) progenitor cells by isolating CD166 expressing cells, using a combination of SHH agonist, BMP inhibitor, Nodal/Activin inhibitor, GSK3 inhibitor, and PORCN inhibitor, allowing for the production of a highly pure and expanded population of mDA progenitor cells without altering their phenotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods are used to produce midbrain dopaminergic progenitor cells from pluripotent stem cells, then the process is simpler, but the productivity is low and contamination is high
Solution Approach 1:
The patent segments the cell production process into distinct stages: initial differentiation of pluripotent stem cells into mDA progenitor cells, purification of CD166+ cells from the differentiated population, and expansion of the purified progenitor cells. This segmentation allows each stage to be optimized independently, achieving high productivity (over 1 billion cells from less than 5 million stem cells) while maintaining process control and reducing contamination through targeted purification at the CD166+ marker stage.
2Manufacturing precision
If purification methods are applied to isolate CD166 expressing cells, then the purity of mDA progenitor cells increases, but the process complexity increases
Solution Approach 1:
The patent uses CD166 surface marker expression as a identifiable characteristic (analogous to a marker or tag) to purify mDA progenitor cells. By isolating CD166+ cells from the differentiated population using flow cytometry or magnetic-activated cell sorting, the method achieves high purity (>90% in some embodiments) of mDA progenitor cells. This marker-based purification approach provides manufacturing precision without requiring complex multi-step purification protocols.
3Quantity of substance
If expansion culture is performed to increase cell numbers, then the quantity of mDA progenitor cells increases, but there is risk of altering cell phenotype
Solution Approach 1:
The patent performs preliminary purification of CD166+ mDA progenitor cells before expansion culture. By isolating a highly pure population of progenitor cells with defined phenotype and differentiation potential prior to expansion, the method ensures that subsequent large-scale culture (producing over 1 billion cells) maintains phenotypic stability. The purified progenitor cells are then expanded under controlled conditions that preserve their midbrain dopaminergic lineage commitment.
Data Source
AI summary
The present invention provides methods of producing, purifying and expanding mDA progenitor cells.